HomePress ReleasesZhejiang University Joins MilliporeSigma’s CRISPR Core Partnership Program

Zhejiang University Joins MilliporeSigma’s CRISPR Core Partnership Program

News Release

  • MilliporeSigma’s global network of more than 80 CRISPR core partners promote ethical scientific exploration with genome editing via access to company’s network of experts
  • Zhejiang University is first in China to use MilliporeSigma’s Arrayed CRISPR Library

MilliporeSigma, a leading science and technology company, today announced a CRISPR core partnership with Zhejiang University in Hangzhou, China. Zhejiang University will be the first institution in China to use MilliporeSigma’s Arrayed CRISPR Library, which will assist in the discovery of the relevance of specific genes in biological functions. The library provides the flexibility and adaptability researchers need, including the ability to be used in high-content screening.

“Our CRISPR Core Partnership Program provides researchers from leading institutions with a platform to actively promote ethical scientific exploration via access to MilliporeSigma’s dedicated technical support, prestigious network of experts, the strongest collection of intellectual property in the life science industry and the latest CRISPR technologies,” said Udit Batra, Member of the Executive Board, Merck KGaA, Darmstadt, Germany, CEO MilliporeSigma. “As a leader in advancing genome editing in biological research and medicine, we look forward to collaborating with Zhejiang University in accordance with the MilliporeSigma CRISPR bioethics policy.”

MilliporeSigma’s CRISPR Core Partnership Program is a network of commercial and research scientists that brings together the top CRISPR academic and commercial institutions in the world to share intellectual resources.

"It is essential for us to be connected to an international network of global collaboration,” said Luo, Jianhong, vice principal of Zhejiang University. “Joining MilliporeSigma’s CRISPR Core Partnership Program gives us the opportunity to work with leading gene-editing scientists and professionals who have the same purpose. We will benefit from the collaboration and the exchange of knowledge and experience.”

MilliporeSigma recognizes that genome editing has resulted in major advancements in biological research and medicine. At the same time, the growing potential of genome-editing technologies has opened scientific, legal and societal concerns. As both a user and supplier of genome-editing technology, MilliporeSigma supports research with genome editing under careful consideration of ethical and legal standards. MilliporeSigma has established an independent, external Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing. The company has developed, defined and transparently published a clear operational position taking into account scientific and societal issues to inform promising therapeutic approaches for use in research and applications.

The Life Science business of MilliporeSigma has secured patents in Australia, China, Canada, Europe, Israel, Singapore, and South Korea covering foundational CRISPR technology. Some of these CRISPR patents are directed to chromosomal integration or cutting of the DNA sequence in eukaryotic cells and insertion of a synthetic exogenous sequence to produce the desired genomic change. Scientists use CRISPR technology to replace disease-associated mutations with beneficial or functional sequences — a critical technology for creating disease models and producing new gene therapy solutions. Other patents are directed to paired nickase technology, which improves CRISPR’s ability to fix diseased genes while not affecting healthy ones. MilliporeSigma recently received its first CRISPR-related patent in the U.S. for proxy-CRISPR technology, which helps modify difficult-to-access regions of the genome, increasing genome coverage.

For more information on MilliporeSigma’s work in genome editing, click here.

About the Life Science business of Merck KGaA, Darmstadt, Germany 

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 23,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany generated sales of € 17.5 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service. 

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

Phone: +1 978-436-1725

Latest Press Releases

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?